

Clinical trials of extended enoxaparin

TrialResults-center www.trialresultscenter.org

1 venous thrombosis

Trial	Treatments	Patients	Trials design and methods
extended enoxaparin vs standard treatment			
Cesarone , 2003 n=NA follow-up: 3 months	Enoxaparin 100UL/Kg twice daily for 3 months versus coumadin (target INR 3) for 3 months.	patients with cancer with DVT	Parallel groups NA
Deitcher , 2006 n=NA follow-up: 12 months	Enoxaparin 1mg/kg twice daily for 5 days followed by 1-1.5mg/kg daily for 175 days versus Enoxaparin 1mg/kg twice daily for 5 days followed by warfarin (target INR 2-3) for a total of 180 days	patients with cancer with DVT and/or PE	Parallel groups none
Meyer , 2002 n=NA follow-up: 3 months	Enoxaparin 1.5 mg/kg daily for 3 monthsmag versus Enoxaparin 1.5 mg/kg daily for 4 days followed by warfarin (target INR 2-3) for 3 months	patients with cancer (solid or hematological; active or in remission but on treatment); with pulmonary embolism and/or DVT and a minimum life expectancy of 3 months	Parallel groups outcome assessment blinded

More details and results :

- antithrombotics for venous thrombosis in patients with cancer at <http://www.trialresultscenter.org/go-Q103>

References

Cesarone, 2003:

Cesarone MR, Ledda A, Nicolaidis A, Belcaro G, Geroulakos G.s=40 Three-month, outpatient, oral anticoagulant treatment in comparison with low-molecular-weight heparin in cancer patients Suplemment to Circulation. 2003; Vol. 108, issue 17:Abstract 2875.

Deitcher, 2006:

Deitcher SR, Kessler CM, Merli G, Rigas JR, Lyons RM, Fareed J Secondary prevention of venous thromboembolic events in patients with active cancer: enoxaparin alone versus initial enoxaparin followed by warfarin for a 180-day period. Clin Appl Thromb Hemost 2006;12:389-96 [17000884]

Meyer, 2002:

Meyer G, Marjanovic Z, Valcke J, Lorcerie B, Gruel Y, Solal-Celigny P, Le Maignan C, Extra JM, Cottu P, Farge D Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med 2002;162:1729-35 [[12153376](#)]

Entry terms: enoxaparin, Lovenox, Clexane